undamentalytics Newsletter
Sign in

Clorox (CLX) stock

Add to watchlist

Add holding +

NYSE: CLX NYSE Household Products Next results ~February 2, 2027

Clorox is a multinational manufacturer and marketer of consumer and professional products. Its consumer brands include Clorox cleaning and disinfecting products, Pine-Sol cleaner, Liquid-Plumr clog removers, Poett home care, Glad bags and wraps, Fresh Step cat litter, Kingsford grilling products, Hidden Valley dressings and sauces, Brita water-filtration products and Burt's Bees natural personal care. For professional and institutional customers it offers Purell, CloroxPro and Clorox Healthcare lines, some of which rely on dispensing systems and recurring purchases of consumables.

The company earns revenue by selling these goods to mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centres, drug, pet and military stores, e-commerce channels and distributors, with Walmart its largest customer. Outside the United States it sells through subsidiaries, licensees, distributors and joint ventures.

Operations are organised into four reportable segments: Health and Wellness, Household, Lifestyle and International. Clorox employs about 9,200 people, operates in roughly 25 countries and sells in around 95 markets. It was founded in Oakland, California, in 1913.

Based on Clorox's 10-K filed August 7, 2026.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Clorox valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Clorox files

Where Clorox stands after its latest 10-K

Revenue for the twelve months to June 2026 was $6.76bn, down 3.7% on a year earlier, faster than -5.7% a quarter earlier. Free-cash-flow margin fell to 5.6% from 11.4% a year earlier. It passes 1 of our 4 financial-health checks.

Our model value for Clorox is under review, so past values are not shown until it is resolved.

Source: 10-K filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 2, 2027 (estimated)

Clorox's trailing-twelve-month revenue fell 3.7% year on year, with a free-cash-flow margin of 5.6%.

Our discounted-cash-flow model values the business at ~$63 per share in the base case (~$42–$92 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 52.6% while net income grew 8.9%: a 61pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 1.7% in a year, so each share owns more of the business.

Things to watch

  • Revenue shrinking. Revenue fell 3.7% over the last 12 months.
  • Weak cash conversion. Free cash flow was 50% of net income over the last 12 months.
  • Short interest rising. Shares sold short rose 21% in a month to 9.8% of tradable shares.

Latest results: FY2027 Q1

Filed November 2, 2026
Earnings per share
$1.55 against an average estimate of $1.07: beat by 45.2%
Revenue
$1.91bn, up 33.3% on a year earlier
Guidance given
net sales growth 13% to 14% (fiscal year 2027); organic sales growth 3.5% to 4.5% (fiscal year 2027)
Next report
November 2, 2026; average EPS estimate $1.33

Clorox's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.2%
  • 1 week+5.1%
  • 1 month+13.4%
  • This year-6.3%
  • 1 year-16.0%
  • 5 years-34.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$6.8B
Net margin
11.2%
EPS (TTM, diluted)
$6.17

Growth

Revenue growth
−3.7%
Change in growth rate
+2.0 pts
Share count change
−1.7%

Cash

Free cash flow (TTM)
$380M
FCF margin
5.6%
Stock pay % of revenue
1.0%

Earnings

Last results
November 2, 2026
Next results (est.)
February 2, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Our research
  3. Leadership
  4. Product
  5. Announcement
  6. Dividend
  7. Results
  8. Guidance
  9. Dividend

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Clorox valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Our value per share comes from a discounted-cash-flow model of Clorox's free cash flow after stock-based pay ( $564M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$100.33$99.07$103.33$120.06$176.49$147.84$119.10$138.73$123.16$111.94$89.90
Market value$13.2bn$13.0bn$13.6bn$15.6bn$22.5bn$18.8bn$14.8bn$17.2bn$15.4bn$13.9bn$11.0bn
+ Net debt (− = net cash)$1.9bn$1.8bn$2.4bn$2.6bn$1.9bn$2.5bn$2.5bn$2.2bn$2.3bn$2.3bn$2.9bn
Enterprise value$15.1bn$14.8bn$15.9bn$18.2bn$24.4bn$21.3bn$17.3bn$19.4bn$17.7bn$16.2bn$13.9bn
Multiples
Price / sales 2.3x2.2x2.2x2.5x3.4x2.6x2.1x2.3x2.2x2.0x1.6x
Price / earnings 20.4x18.6x16.5x19.0x24.0x26.5x31.9x115.6x54.9x17.2x14.6x
Price / free cash flow 21.8x20.6x17.4x19.8x17.4x19.9x27.6x18.5x31.8x18.3x29.0x
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

67 /100

Moderate moat

How hard Clorox's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Net income has been a median 13.5% of total assets over 10 years.

  • Pricing power 14 / 20

    Gross margin has been a median 44.0%, moving by 3.2 percentage points (standard deviation) across 10 years.

  • Durability 4 / 20

    Net margin has been a median 11.2%; its worst year was 1.0%.

  • Cash conversion 16 / 20

    Free cash flow was positive in 10 of 10 years, at a median 11.6% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 4.1% over five years; stock-based pay has been a median 0.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (72 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $5.70 +3% $7.6bn +14%
Next $6.13 +8% $7.8bn +2%

Next year's EPS estimate has moved −4.9% in 90 days, across 18 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −2.1% on 90 days ago. In the last 30 days, 0 analysts raised Clorox's forecast and 5 cut it.

Consensus EPS forecast Clorox, last 90 days
$5.60 $5.80 $6.00 $6.20 $6.40 $6.60 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $5.82 Current fiscal year, 60 days ago: $5.81 Current fiscal year, 30 days ago: $5.75 Current fiscal year, 7 days ago: $5.70 Current fiscal year, Now: $5.70 $5.70 Next fiscal year, 90 days ago: $6.45 Next fiscal year, 60 days ago: $6.29 Next fiscal year, 30 days ago: $6.26 Next fiscal year, 7 days ago: $6.13 Next fiscal year, Now: $6.13 $6.13

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $5.82$6.45
60 days ago $5.81$6.29
30 days ago $5.75$6.26
7 days ago $5.70$6.13
Now $5.70$6.13

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $1.07 $1.55 +45.2%
Jun 2026 $1.65 $1.66 +0.9%
Mar 2026 $1.54 $1.64 +6.2%
Dec 2025 $1.43 $1.39 −3.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 3, 2026
  • Net sales fiscal year 2027 13% growth to 14% growth GAAP
    “Net sales are expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition.” source
  • Organic sales fiscal year 2027 3.5% growth to 4.5% growth Non-GAAP
    “Organic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown in the prior fiscal year.” source
  • Diluted EPS fiscal year 2027 $5.41 to $5.71 GAAP
    “Diluted EPS is expected to be between $5.41 and $5.71, a year-over-year increase of 12% to 19%, respectively.” source
  • Adjusted EPS fiscal year 2027 $5.70 to $6.00 Non-GAAP
    “Adjusted EPS is expected to be between $5.70 and $6.00, or an increase between 3% and 8%, respectively.” source
  • Gross margin fiscal year 2027 about 42%
    “Gross margin is expected to be about 42%, reflecting higher-than-normal inflationary headwinds and negative mix more than offsetting the benefits from cost savings.” source
  • Selling and administrative expenses fiscal year 2027 about 16%
    “Selling and administrative expenses are expected to be about 16% of net sales.” source
Show 3 more items
  • Advertising and sales promotion spending fiscal year 2027 about 10%
    “Advertising and sales promotion spending is expected to be about 10% of net sales.” source
  • Advertising and sales promotion spending · retail businesses fiscal year 2027 about 11%
    “This assumes over 11% of net sales for its retail businesses.” source
  • effective tax rate fiscal year 2027 about 23%
    “The company's effective tax rate is expected to be about 23%.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Clorox's revenue by +16.6% next year and +2.1% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+21.5%, weight 56%) , management guidance (+21.5%, weight 19%) and the company's own record (+2.0%, weight 25%) . How the weights are set.

Analyst recommendations

19 analysts, Nov 2026
Buy15%
Hold1474%
Sell421%

Monthly trend

  1. Nov 2026142219
  2. Oct 2026142219
  3. Sep 2026142219

Counts of recommendations published by analysts covering Clorox, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.8%
of tradable shares
Days to cover
3.56
at average volume
Short interest, 1 month
+21%
to October 15, 2026
Held by institutions
88%
of shares
Held by insiders
0.7%
of shares
Employees
9,200
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −16.0%

$107.02 on October 31, 2025 to $89.90

ThenNowEffect
Revenue (last 12 months) $7.1bn $6.8bn −4.8%
Net margin 11.4% 11.2% −1.9%
P/E multiple 16.4x 14.6x −11.2%
Share count 124m 123m +1.4%

Biggest factor: p/e multiple.

Last 3 years −19.3%

$111.42 on November 3, 2023 to $89.90

ThenNowEffect
Revenue (last 12 months) $7.4bn $6.8bn −8.5%
Net margin 2.0% 11.2% +454.6%
P/E multiple 92.9x 14.6x −84.3%
Share count 124m 123m +1.3%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CLX−12%−17%+5%+18%−36%−6%
Industry peers (median)+9%−20%+4%+8%−19%+22%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CLX42%50%58%50%17%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CLX−28%−33%−33%−18%−38%−35%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 59% from August 4, 2020 to October 2, 2026. Getting back needed a 143% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$79.26 – $122.35
From 52-week high
−26.5%
vs 50-day average
+3.2%
vs 200-day average
−7.3%
Volatility (1 year)
32%
Beta vs S&P 500
0.32

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 6 down
typical move ±5.4%
After a week
5 up, 6 down
typical move ±5.7%
After a month
5 up, 6 down
typical move ±6.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 +9.6% +3.3% +12.7% +0.6%
April 30, 2026 −8.1% +1.3% −2.8% −6.0%
February 3, 2026 +4.0% −1.3% +7.2% +0.4%
November 3, 2025 −1.8% −1.0% −6.9% −6.5%
July 31, 2025 −2.4% −2.0% −0.1% −5.4%
May 5, 2025 −2.9% −1.4% −0.7% −6.8%
February 3, 2025 −6.6% 0.0% −7.3% −5.6%
October 30, 2024 +1.1% −2.3% +3.7% +6.6%
August 1, 2024 +9.2% −3.3% +9.4% +21.0%
April 30, 2024 −6.2% −1.9% −5.2% −13.4%
February 1, 2024 +7.6% +2.4% +6.2% +3.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Clorox
$6.6B $6.8B $7B $7.2B $7.4B $7.6B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $7.4B Revenue (TTM), FY24 Q1: $7B Revenue (TTM), FY24 Q2: $7.3B Revenue (TTM), FY24 Q3: $7.2B Revenue (TTM), FY24 Q4: $7.1B Revenue (TTM), FY25 Q1: $7.5B Revenue (TTM), FY25 Q2: $7.2B Revenue (TTM), FY25 Q3: $7B Revenue (TTM), FY25 Q4: $7.1B Revenue (TTM), FY26 Q1: $6.8B Revenue (TTM), FY26 Q2: $6.8B Revenue (TTM), FY26 Q3: $6.8B $6.8B

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $7.4B
FY24 Q1 $7B
FY24 Q2 $7.3B
FY24 Q3 $7.2B
FY24 Q4 $7.1B
FY25 Q1 $7.5B
FY25 Q2 $7.2B
FY25 Q3 $7B
FY25 Q4 $7.1B
FY26 Q1 $6.8B
FY26 Q2 $6.8B
FY26 Q3 $6.8B
Revenue growth, TTM YoY Clorox
-10% -5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 4.0% Revenue growth, TTM YoY, FY24 Q1: -0.1% Revenue growth, TTM YoY, FY24 Q2: 3.5% Revenue growth, TTM YoY, FY24 Q3: 0.5% Revenue growth, TTM YoY, FY24 Q4: -4.0% Revenue growth, TTM YoY, FY25 Q1: 6.2% Revenue growth, TTM YoY, FY25 Q2: -2.0% Revenue growth, TTM YoY, FY25 Q3: -2.6% Revenue growth, TTM YoY, FY25 Q4: 0.2% Revenue growth, TTM YoY, FY26 Q1: -9.3% Revenue growth, TTM YoY, FY26 Q2: -5.7% Revenue growth, TTM YoY, FY26 Q3: -3.7% -3.7%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 4.0%
FY24 Q1 -0.1%
FY24 Q2 3.5%
FY24 Q3 0.5%
FY24 Q4 -4.0%
FY25 Q1 6.2%
FY25 Q2 -2.0%
FY25 Q3 -2.6%
FY25 Q4 0.2%
FY26 Q1 -9.3%
FY26 Q2 -5.7%
FY26 Q3 -3.7%
FCF margin (TTM) Clorox
4% 6% 8% 10% 12% 14% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 12.6% FCF margin (TTM), FY24 Q1: 11.3% FCF margin (TTM), FY24 Q2: 10.0% FCF margin (TTM), FY24 Q3: 7.9% FCF margin (TTM), FY24 Q4: 6.8% FCF margin (TTM), FY25 Q1: 9.0% FCF margin (TTM), FY25 Q2: 9.7% FCF margin (TTM), FY25 Q3: 11.4% FCF margin (TTM), FY25 Q4: 10.7% FCF margin (TTM), FY26 Q1: 9.4% FCF margin (TTM), FY26 Q2: 11.5% FCF margin (TTM), FY26 Q3: 5.6% 5.6%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 12.6%
FY24 Q1 11.3%
FY24 Q2 10.0%
FY24 Q3 7.9%
FY24 Q4 6.8%
FY25 Q1 9.0%
FY25 Q2 9.7%
FY25 Q3 11.4%
FY25 Q4 10.7%
FY26 Q1 9.4%
FY26 Q2 11.5%
FY26 Q3 5.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Jun 2009 2010 Jun 2010 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 LTM Mar 2026
Income
Revenue 5,158 5,234 5,231 5,468 5,623 5,514 5,655 5,761 5,973 6,124 6,214 6,721 7,341 7,107 7,389 7,093 7,104 6,760
Gross profit 2,204 2,319 2,273 2,304 2,391 2,356 2,465 2,598 2,671 2,675 2,728 3,063 3,199 2,545 2,908 3,048 3,213 2,964
Net income 537 603 557 541 572 558 580 648 701 823 820 939 710 462 149 280 810 756
Diluted EPS $3.79 $4.24 $4.02 $4.09 $4.30 $4.23 $4.37 $4.92 $5.33 $6.26 $6.32 $7.36 $5.58 $3.73 $1.20 $2.25 $6.52 $6.17
Growth (year on year)
Revenue −2.2% +1.5% −0.1% +4.5% +2.8% −1.9% +2.6% +1.9% +3.7% +2.5% +1.5% +8.2% +9.2% −3.2% +4.0% −4.0% +0.2% −3.7%
Net income +16.5% +12.3% −7.6% −2.9% +5.7% −2.4% +3.9% +11.7% +8.2% +17.4% −0.4% +14.5% −24.4% −34.9% −67.7% +87.9% +189.3% +8.9%
Diluted EPS +17.3% +11.9% −5.2% +1.7% +5.1% −1.6% +3.3% +12.6% +8.3% +17.4% +1.0% +16.5% −24.2% −33.2% −67.8% +87.5% +189.8% +10.9%
Margins
Gross margin 42.7% 44.3% 43.5% 42.1% 42.5% 42.7% 43.6% 45.1% 44.7% 43.7% 43.9% 45.6% 43.6% 35.8% 39.4% 43.0% 45.2% 43.8%
Net margin 10.4% 11.5% 10.6% 9.9% 10.2% 10.1% 10.3% 11.2% 11.7% 13.4% 13.2% 14.0% 9.7% 6.5% 2.0% 3.9% 11.4% 11.2%
Free-cash-flow margin 10.5% 11.8% 9.0% 7.7% 10.4% 11.4% 13.2% 10.5% 10.6% 12.8% 12.6% 19.2% 12.9% 7.5% 12.6% 6.8% 10.7% 5.6%
Cash flow
Cash from operations 738 819 698 612 775 767 874 778 865 976 992 1,546 1,276 786 1,158 695 981 576
Capital spending 196 201 228 192 190 137 125 172 231 194 206 254 331 251 228 212 220 196
Free cash flow 542 618 470 420 585 630 749 606 634 782 786 1,292 945 535 930 483 761 380
Stock-based pay 58 60 32 27 35 36 32 45 51 53 43 50 50 52 73 74 81 66
Free cash flow after stock pay 484 558 438 393 550 594 717 561 583 729 743 1,242 895 483 857 409 680 314
Balance sheet
Cash 206 87 259 267 299 329 382 401 418 131 111 871 319 183 367 202 167 1,187
Total debt 3,149 2,795 2,584 2,721 2,372 2,313 2,191 2,312 2,195 2,483 2,683 2,780 2,784 2,711 2,527 2,485 2,488 4,078
Net debt (negative = net cash) 2,943 2,708 2,325 2,454 2,073 1,984 1,809 1,911 1,777 2,352 2,572 1,909 2,465 2,528 2,160 2,283 2,321 2,891
Diluted shares 140m 142m 138m 132m 133m 132m 133m 132m 132m 132m 130m 128m 127m 124m 124m 125m 124m 123m
Returned to shareholders
Dividends 258 282 303 315 335 368 385 398 412 450 490 533 558 571 583 595 602 602
Buybacks — 150 655 225 128 260 434 254 183 271 661 248 905 25 0 0 332 331
Total returned 258 432 958 540 463 628 819 652 595 721 1,151 781 1,463 596 583 595 934 933

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 3 checks passed · September 30, 2026
What it owns · $7.8bn
Short-term assets $1.9bnLonger-term assets $5.9bn
What it owes, and who funded it · $7.7bn
Short-term liabilities $3.0bnLonger-term liabilities $4.8bnShareholders' equity $-39m
  • Short-term assets cover short-term liabilities $1.9bn of assets due within a year against $3.0bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.9bn short-term assets against $4.8bn of longer-dated liabilities.
  • More cash than debt $184m of cash against $4.0bn of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Clorox's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$331M
Dividends (TTM)
$602M
Returned to shareholders
246%
of free cash flow
Diluted share count
−1.7%
year over year
Total shareholder yield
8.6%
dividends 5.5% + buybacks 3.0% of market value
Dividend payout ratio
80%
of net income paid out
R&D spending
1.7%
of revenue
Sales & admin spending
15.7%
of revenue

Competitors: side by side with peers

Closest by revenue in household products
Last 12 months unless stated CLX CHD REYN CENT ENR SPB Median
Revenue, last 12 months $6.8bn $6.2bn $3.8bn $3.1bn $3.0bn $2.9bn $3.1bn
Revenue growth, last 12 months −3.7% 1.7% 2.7% −1.2% 2.2% 0.8% 1.7%
Revenue growth, 3-year average −1.9% 2.6% −0.7% −1.9% 0.6% −0.6% −0.7%
Revenue growth, latest quarter 33.3% 1.0% 0.6% −8.2% 1.2% 7.7% 1.1%
Gross margin 43.8% 46.1% 25.1% 32.5% 36.8% 39.6% 43.8%
Operating margin — 18.0% — 8.1% — 4.0% 11.5%
Operating margin, 3-year average — 16.0% — 7.4% — 4.6% 15.9%
Net margin 11.2% 12.4% 9.1% 5.4% 2.7% 2.8% 9.1%
Cash from operations / revenue 8.5% 19.3% 13.3% 12.7% 7.3% 11.6% 12.7%
Free-cash-flow margin 5.6% 16.9% 8.5% 11.2% 5.0% 10.2% 10.2%
Free-cash-flow margin, 3-year average 8.3% 16.0% 10.2% 10.1% 6.6% −1.2% 10.2%
Stock pay / revenue 1.0% 1.2% 0.5% 0.5% 0.9% 0.8% 0.8%
Change in share count −1.7% −3.3% 0.3% −4.5% −5.6% −12.5% −1.5%

Median of all 13 companies we cover in household products. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$10B
Institutions reporting
1,041
Shares held vs prior quarter
▲ 4.3%
Positions opened / closed
111 / 157

Top buyers and sellers, Q2 2026: 513 institutions bought and 511 sold ; the biggest buyer was Millennium Management LLC (+1.4M shares) and the biggest seller Point72 Asset Management, L.P (−1.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $959M 10.0M 9.6% ▼ 1.3%
State Street Corp $805M 8.4M 8.1% ▲ 2.2%
Vanguard Capital Management LLC $754M 7.9M 7.6% ▲ 0.6%
Invesco Ltd. $574M 6.0M 5.8% ▲ 23.7%
Vanguard Portfolio Management LLC $554M 5.8M 5.6% ▲ 0.3%
Geode Capital Management, LLC $310M 3.3M 3.1% ▲ 1.1%
Van Eck Associates Corp $284M 3.0M 2.9% ▼ 7.6%
Morgan Stanley $214M 2.2M 2.2% ▼ 17.3%
Millennium Management LLC $198M 2.1M 2.0% ▲ 199.6%
UBS Group AG $189M 2.0M 1.9% ▲ 116.6%
Bank Of America Corp $180M 1.9M 1.8% ▲ 34.0%
Citadel Advisors LLC $168M 1.8M 1.7% ▲ 23.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Clorox's complete shareholder register. Values are as reported by the filers ; 4 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $845,640 2 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $845,640 net buying
Insider Date Trade Shares Price Value
Breber Pierre R Director May 5, 2026 Buy 5,000 $85.82 $429,124
Breber Pierre R Director November 21, 2025 Buy 4,000 $104.13 $416,516

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 42 trades and filings

In the last 12 months, 1 member of Congress disclosed 1 purchase and 2 sales of Clorox shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (full), $1,001 - $15,000, traded May 15, 2026, filed June 8, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded December 19, 2025, filed January 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (full), $1,001 - $15,000, traded November 12, 2025, filed December 15, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around February 2, 2027 estimated from the company's past filing pattern, not announced

  • November 2, 2026
  • August 3, 2026
  • April 30, 2026
  • February 3, 2026
  • November 3, 2025
  • July 31, 2025

Recent SEC filings

Data status

When each part of this page on Clorox was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Clorox in brief

What does Clorox do?
Clorox is a US-listed company in the household products industry. Its financial year ends in June.
What is Clorox's stock ticker?
Clorox trades under the ticker CLX on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Clorox's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Clorox reported revenue of $6.8B, 3.7% lower than a year earlier, according to its SEC filings.
What is Clorox's free cash flow?
Clorox's free-cash-flow margin is 5.6% of revenue over the trailing twelve months.
Who are Clorox's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., State Street Corp and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Clorox buying back stock, and does it pay a dividend?
Clorox spent $331M on share repurchases over the trailing twelve months, and its diluted share count fell 1.7% over the year.
What is Clorox's market cap?
On November 2, 2026, Clorox's market capitalisation was about $11B, with a price-to-earnings ratio of 14.6 and net debt of $2.9B. Market figures come from third-party market data and may be delayed.
Does Clorox pay a dividend?
Yes: Clorox paid $602M in dividends over the trailing twelve months, a dividend yield of 5.54% and a payout ratio of 79.6%.
Who are Clorox's competitors?
In our Household Products peer group, the companies closest to Clorox are Church & Dwight, Reynolds Consumer Products Inc., Central Garden & PET Co, Energizer Holdings, Inc. and Spectrum Brands Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Clorox's.
Are insiders buying or selling Clorox stock?
Over the last 12 months, Clorox's directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Clorox's next earnings date?
Around February 2, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Clorox announces its own schedule.